^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Triple Negative Breast Cancer
    Drug:Cosela (trilaciclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    G1 Therapeutics Press Release
    Title:

    G1 THERAPEUTICS RECEIVES FAST TRACK DESIGNATION FROM U.S. FOOD AND DRUG ADMINISTRATION FOR COSELA™ (TRILACICLIB) IN COMBINATION WITH CHEMOTHERAPY FOR THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER

    Published date:
    07/19/2021
    Excerpt:
    G1 Therapeutics, Inc....today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to COSELA™ (trilaciclib) investigation for use in combination with chemotherapy for the treatment of locally advanced or metastatic triple negative breast cancer (TNBC).
    Secondary therapy:
    Chemotherapy